Alterity Therapeutics (ASX:ATH) Other Gross PPE: A$0.19 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ATH Alterity Therapeutics Ltd ASX:ATH
28 GF Score
Price A$0.50
! 1 Warning Sign
View Full Analysis

What is Alterity Therapeutics Other Gross PPE?

Alterity Therapeutics ASX:ATH -0.99% 28 Other Gross PPE is A$0.19 Mil as of Jun. 2026. GuruFocus rates ASX:ATH with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Alterity Therapeutics's Other Gross PPE for the quarter that ended in Jun. 2026 was A$0.19 Mil.

Alterity Therapeutics's quarterly Other Gross PPE declined from Dec. 2025 (A$0.10 Mil) to Mar. 2026 (A$0.00 Mil) but then increased from Mar. 2026 (A$0.00 Mil) to Jun. 2026 (A$0.19 Mil).

Alterity Therapeutics's annual Other Gross PPE declined from Jun. 2024 (A$0.19 Mil) to Jun. 2025 (A$0.16 Mil) but then increased from Jun. 2025 (A$0.16 Mil) to Jun. 2026 (A$0.19 Mil).

Alterity Therapeutics Other Gross PPE Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Other Gross PPE Chart

Alterity Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.73 0.19 0.16 0.19

Alterity Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.00 0.10 0.00 0.19
ASX:ATH
28GF Score
Alterity Therapeutics Ltd ASX:ATH
Other Gross PPE is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Frequently Asked Questions Learn more about Other Gross PPE →
What does a Other Gross PPE of A$0.19 Mil mean?
Alterity Therapeutics (ASX:ATH) has a Other Gross PPE of A$0.19 Mil as of Jun. 2026. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Other Gross PPE too high?
Alterity Therapeutics' current Other Gross PPE is A$0.19 Mil. Overall, Alterity Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Other Gross PPE compare to VRTX and REGN?
Alterity Therapeutics' Other Gross PPE of A$0.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Gross PPE for a Biotechnology company?
A good Other Gross PPE depends on the Biotechnology industry context. However, Other Gross PPE should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Gross PPE mean?
A high Other Gross PPE can signal that a stock is expensive relative to its fundamentals. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current Other Gross PPE is A$0.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Other Gross PPE of A$0.19 Mil. The current Other Gross PPE is A$0.19 Mil. Alterity Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Gross PPE calculated?
Other Gross PPE is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Other Gross PPE is A$0.19 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
28GF Score

Get the complete analysis for ASX:ATH

Other Gross PPE is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.50
Price